The Best Biotech Stocks for 2013 Are Now Within Your Reach

Garrett Baldwin

Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.

But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.

For some time, it was best to stick to large-scale pharmaceutical companies with a strong yield and avoid mass speculation in hit-or-miss penny stocks.

Well, not any more. Shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) – which tracks industry returns – are up a staggering 42% since the beginning of the year, and the health/biotech industry has the highest returns of any sector for the year.

And you haven't seen anything yet…

With one of the most exciting biotech companies now joining the NYSE and another setting its focus on an uplisting, we're seeing major changes in the biotech industry and investment. And there are companies poised to become the best biotech stocks you can find right now.

Biotech Stocks Soar on Life-Changing Innovations

Many of the best performing stocks offer products and services that weren't even technologically possible just two decades ago. But new levels of biotechnological innovation have opened the door to massive amounts of wealth to investors throughout history.

The biotech industry is the hottest place you can put your money right now.

Since the beginning of the year, a number of biotech stocks have absolutely soared, drawing a lot of attention to the sector and its potential.

Cancer therapy firm Amgen Inc. (NASDAQ: AMGN) is up 24% on the year, biopharma producer Gilead Sciences (NASDAQ: GILD) is up 69%, molecular diagnostic company Myriad Genetics (NASDAQ: MYGN) is up 13%, and global biopharmaceutical company Celgene Corp. (NASDAQ: CELG) is up a whopping 72% in 2013.

Editor's Note: The FDA has recently cleared a device with the power to achieve the ultimate goal of medicine: It can put an end to almost any disease. Industry insiders project that massive demand for this less-than $50 device will generate $7 trillion in revenue. Yet, since it's been kept out of the press, you can secure a piece of the patent rights at an incredible discount right now.

In the 1990s, some of these shares were penny stocks, doing their best to survive the trials of speculation while investors parked their money in the booming internet industry.

And while dabbling in penny stocks is a still a bold strategy these days, there is another way to speculate on whether a company is about to enter the mainstream. And this one is far more lucrative in the long-run.

Garrett Baldwin

About the Author

Browse Garrett's articles | View Garrett's research services

Garrett Baldwin is a globally recognized research economist, financial writer, and consultant with degrees from Northwestern, Johns Hopkins, Purdue, and Indiana University. He is a seasoned financial and political risk analyst, with a focus on stocks, hedge funds, private equity, blockchain, and housing policy. He has conducted risk assessment projects for clients in 27 countries, and consulted on policy and financial operations for some of the nation's largest financial institutions, including a $1.5 trillion credit fund, a $43 billion credit and auto loan giant, as well as two of the largest Wall Street banks by assets under management.

Garrett joined Money Map Press as an economist and researcher in 2011, specializing in alternative strategies with an emphasis on fundamental and technical analysis.

… Read full bio